These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Losigamone. Dr Willmar Schwabe.
    Author: Willmore LJ.
    Journal: Curr Opin Investig Drugs; 2001 Dec; 2(12):1763-6. PubMed ID: 11892943.
    Abstract:
    Losigamone is a potential antiepileptic under development by Schwabe, which is currently in phase III clinical trials. By August 2000, Schwabe was seeking suitable partners to collaborate in the completion of the phase III trials and further development. The exact mode of action of losigamone is unclear but it does not involve specific binding of GABA, flunitrazepam or t-butyl-bicyclophosphorothionate (TBPS) to their receptors. Data concerning the interaction of losigamone with GABA-A receptor channels, however, are inconsistent; it does not significantly modify the GABAergic inhibitory postsynaptic potentials (IPSPs) in hippocampal slices, although it potentiates GABA-induced chloride influx in primary spinal cord neuron cultures. Another suggested possible mechanism of action for losigamone is K+ channel activation.
    [Abstract] [Full Text] [Related] [New Search]